Replies to post #142266 on PharmaCyte Biotech Inc (PMCB)

[efood125]

Next up...Nasdaq. I think a partnership with Primegen is very possible. Maybe a reverse partnership as pmcb is public company and Primegen is private.

[ferenc]

Selling your shares was a bad timing ...good luck.

[livendi]

Just be ready for something big. Something big is coming. 50 bill shares worth. Awful. 1 day kw and cronies and anyone else that helped perpetuate this pos pump and dump scam will have to answer for it 1 day.absolute scumbags. Again Nothing gets by the trinity. God bless all

[ferenc]

My be my comment was baseless …now I am concern to.

[longboarder7892]

LAGUNA HILLS, Calif. --(BUSINESS WIRE)-- PharmaCyte Biotech, Inc. (OTCQB: PMCBD) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that The Nasdaq Stock Market LLC (Nasdaq) has approved the listing of the Company’s common stock on Nasdaq. The Company’s common stock will be listed on Nasdaq under the symbol “PMCB.” PharmaCyte also announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock (or pre-funded warrants to purchase common stock in lieu of common stock) and warrants to purchase shares of common stock in an underwritten public offering.

chemo without side effects
Once the street hears about this deal it will go ballistic

Dr Hidalgo as the PI -All the big Pharma are watching what he is working on and dont leave out BMY which he sits on the board of..
NEW YORK --(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has elected Manuel Hidalgo Medina , M.D., Ph.D., to the Board, effective June 1, 2021 . Dr. Hidalgo will serve as a member of the Science & Technology Committee of the Board of Directors.

Dr. Hidalgo , 53, is currently chief of the division of hematology and medical oncology at Weill Cornell Medicine and New York-Presbyterian/Weill Cornell Medical Center where he is responsible for leading clinical and translational research in hematology, vascular biology and oncology. Dr. Hidalgo is also the E. Hugh Luckey distinguished professor of medicine and associate director for clinical services at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine.
He brings to the Board more than 20 years of experience in translational and clinical research in anticancer drug development with a particular emphasis in gastrointestinal cancers. He has also led the early clinical development of new anticancer agents for pancreatic cancer among other solid tumor cancers.